BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

Bridgewest completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer

The newly acquired facility is a cGMP manufacturing plant that produces a wide variety of high quality sterile injectable drug products. The site and ...

April 04, 2023 | News

Australia Diabetes Market Projected to Reach $5.96 Billion by 2028, Reports Research and Markets

Research and Markets, a leading market research company, has released a report on the Australia Diabetes Market projecting it to reach ...

April 02, 2023 | News

Earable Neuroscience and Excelpoint Partner to Commercialize AI-Powered FRENZ Brainband for Global Sleep Pandemic

Since the COVID-19 pandemic began, researchers around the world have documented a surge in sleep disorders which affect overall health, safety and qualit...

March 31, 2023 | News

Noxopharm CEO Discusses SOF-VAC™, a Promising Vaccine Enhancer for mRNA Vaccines

In an interaction with BioPharma APAC, Noxopharm CEO Dr. Gisela Mautner discussed the company's newly announced proprietary product candidate, SOF-VAC&trad...

March 31, 2023 | Influencers

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small mole...

March 30, 2023 | Regulatory

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antig...

March 29, 2023 | News

Noxopharm Announces Novel mRNA Vaccine Enhancer

Proprietary SOF-VACTM asset with potential to make mRNA vaccines safer, better tolerated by patients and more cost-effective to manufacture Preclin...

March 28, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

March 27, 2023 | News

Enveric Biosciences Selects Australian CRO, Avance Clinical

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of nove...

March 27, 2023 | News

See-Mode Technologies' AI-powered Ultrasound Software Secures Regulatory Approval in Australia and New Zealand.

"We are thrilled to receive regulatory approvals for our product in Australia and New Zealand," said Dr Milad Mohammadzadeh, Co-Founder...

March 22, 2023 | News

FDA approves expanded indication for Telix's Illuccix® for PSMA-directed therapy

The label expansion means Illuccix is now approved in the U.S. to identify and select patients who are candidates for the only FDA-approved prostate-specif...

March 16, 2023 | News

Telix's Revolutionary Kidney Cancer Imaging Study Takes Center Stage at EAU's 'Game Changing' Session

The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud University Medical Centre (Neth...

March 14, 2023 | News

Telix to Present ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EAU

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...

March 09, 2023 | News

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer

The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product containing the genetic modifications incorporated into ...

February 27, 2023 | News

Stay Connected